Related Experiment Video
Updated: Aug 6, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A
Bruno Bombaci1, Fortunato Lombardo1, Marta Bassi2
1Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi," University of Messina, Messina, Italy.
Introduction:
Evidence on the long-term durability of glycemic control beyond the first year of automated insulin delivery therapy remains limited, particularly in large multicenter pediatric cohorts. The present study aimed to evaluate long-term effectiveness and identify determinants of sustained optimal outcomes over 3 years of MiniMed™ 780G use in youth with type 1 diabetes (T1D).
Materials And Methods:
In this longitudinal, multicenter, real-world study, 359 youth with T1D (median age 12.2 years, 50.9% female) from 20 Italian pediatric diabetes centers were followed for 3 years after MiniMed 780G initiation. Glucose metrics, insulin delivery parameters, device settings, and engagement indicators were analyzed at 1, 2, and 3 years. Longitudinal changes were assessed using linear mixed-effects models. Multivariable logistic regression identified predictors of achieving time in tight range target (TITR ≥ 50%) at 3 years.
Results:
Median time in range (TIR) remained within international targets but declined modestly from 75% at 1 year to 74% at 3 years (P = 0.002). The percentage of automatic correction boluses increased over time, whereas user-initiated boluses and carbohydrate entries declined (P < 0.001). Youth with higher TIR at 1 year showed a progressive reduction in TIR and greater increase in automated corrections (time × group interaction P < 0.001). At 3 years, higher SmartGuard use (odds ratio [OR]: 1.13, 95% confidence interval [CI]: 1.03-1.23; P = 0.007), optimal system settings (OR: 3.21, 95% CI: 1.33-7.77; P = 0.010), and lower automatic correction boluses (OR: 0.84, 95% CI: 0.80-0.89; P < 0.001) were independently associated with achieving TITR ≥50%.
Conclusions:
MiniMed 780G provides sustained glycemic control over 3 years. However, progressive reliance on automated corrections and reduced user engagement may attenuate tight glycemic control, highlighting the need for ongoing education and proactive device optimization.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Type I Diabetes III: Clinical Manifestations
Diabetes Mellitus: Type 2 and Gestational